^
    Back
    Association details:
    Biomarker:HER-2 expression
    Cancer:Rhabdomyosarcoma
    Drug Class:T-lymphocyte cell therapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Transl Oncol
    Title:

    Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma

    Published date:
    10/01/2021
    Excerpt:
    High cell-surface expression of HER2 was observed in all the cell lines….To the best of our knowledge, this is the first study to indicate that HER2-targeted CAR T cells are directly effective against molecularly defined synovial sarcoma cells.
    DOI:
    https://doi.org/10.1016/j.tranon.2021.101227